Healthcare Journal Blog’s Detailed Documentation of Pharmacy Automation Systems Market

Pharmacy use automation systems to meet broad need of pharmacies. Automation system in pharmacy reduces their medical inventory and improves cash flow. Pharmacy automation system includes medication dispensing cabinets, packaging & labeling machines, IV pharmacy, robotic dispensing machines, carousel storage and tablet splitters. This helps patients especially the elderly, take their medication at the right times. Some of the advantages of pharmacy automation systems include higher reliability and accuracy, flexible design to meet individual pharmacy requirements, reduces drug wastage and medication cost, minimize time-consuming labor work and improve work efficiency, increases pharmacist time to consult with patients and enhances patient’s experiences.

 

Use of pharmacy automation system helps in improving efficiency and productivity of the pharmacy is a primary driver for the pharmacy automation system market growth. Beside this, reduce medication errors, rush in pharmacy centers, reduce inventory and space saving design of the machine are also some of the factors leading to increase demand for pharmacy automation systems. However, high cost of implementation of automation system to hinder the market growth. Continually developing new solutions to aid pharmacies in increasing throughput can create more opportunities in near future.

 

Geographically, North America held the largest market share in 2017 and is expected to dominate throughout the forecast period. Meanwhile Europe is the second largest market for pharmacy automation system. In North America, heavy investment is been done in pharmacy automation in order to minimize the medication errors. This investment was done in pharmacy automation as it was found that error in medication prescription dispensing was a leading cause of death in North America after cancer, heart attack and stroke. Asia pacific is expected to grow at the highest CAGR on account of rising awareness and investment in healthcare infrastructure.

Medicine Handlings | Global Alzheimer’s Disease

Alzheimer’s disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. Cholinesterase inhibitors are set to treat symptoms related to memory, language, thinking, judgment and other thought processes. The alzheimer’s drugs prevent the breakdown of a chemical messenger in the brain. It is the cause of 60–70% of cases of dementia.

The cholinergic, memantine, combined drug and other drugs are used to treat the Alzheimer’s disease. The presence of high revenue-generating drugs such as Donepezil, Exelon, and galantamine is a key driver, for the growth of cholinergic drug. Memantine, the fifth Alzheimer’s drug, is an NMDA (N-methyl-D-aspartate) receptor antagonist has dominated the drug class segment due to large number of patent expiry of major products and a restricted number of drugs to treat alzheimer’s disease.

The rising occurrence of neurodegenerative diseases among the elderly and a healthy support from governments across developed countries has led to the development of new drugs and therapies which has helped in the development and growth of the Alzheimer’s drugs market .Additionally lack of Duchenne muscular dystrophy (DMD) is another factor that promotes the growth of the market. The lack of DMDs extends the treatment schedule for Alzheimer’s disease, which in turn, increases the healthcare costs for patients.

Among the regions, North America is expected to the largest market for alzheimer’s drugs. The large number of patients suffering from the alzheimer’s disease, high purchasing power for expensive drugs and compensation policies for the treatment of this disease is likely to boost the growth in this market. The increasing awareness about neurodegenerative diseases in Asia Pacific region will boost the growth of the global alzheimer’s drugs market in the next coming years.

Ventricular Assist Devices Market | Current State and Challenges

North America has amassed the growth in Ventricular Assist Devices (VAD) Market

The global Ventricular Assist Devices (VAD) Market has been dominated by the North America region over the historic period 2015-16 followed by Europe. Rising occurrence of cardiovascular diseases, developed healthcare infrastructure, high patient awareness levels and better compensation policies for implantation procedures is the key factors drives the growth in this region. According to CDC, about 5.7 million adults in the U.S. have heart failure. American Heart Association says that in the U.S. approximately 5.5 million people are affected by heart failure.

Tobacco consumption, junk food, alcohol addiction, substance abuse, are likely to contribute towards cardiovascular disease population.

Growth in incidence of patients with heart failure and lack of heart donors is likely to boost the growth of the market. In addition, rising the incidence of cardiovascular diseases such as coronary artery disease, hypertension, and heart failure. Moreover, growing the occurrence of diabetes, genetic factors, lifestyle factors such as tobacco consumption, junk food, alcohol addiction, substance abuse, are likely to contribute towards cardiovascular disease population. Says Miss. Hetal Patel a research analyst at Infinium Global Research

Innovation of new product will bring more opportunities to the market 

Research and development carried on innovation of novel device is likely to bring more opportunities to the market. For instance, in 2017, Heartmate III has been approved by the FDA. It is smaller than its predecessor HeartMate II, and uses a full maglev impeller instead of the cup-and-ball bearing system found in HeartMate II. 

Business expansion and innovation of products is the key strategy of the leading player 

The merger and acquisition and business expansion are the key strategy of the leading player in this market. For instance, Abbott signs definitive agreement to acquire St. Jude Medical to create a premier medical device leader with top positions in high-growth cardiovascular markets, including atrial fibrillation, structural heart and heart failure, in 2016. Medtronic acquires HeartWare International to expand heart failure portfolio in 2016. Abiomed Inc. received pre-market approval from FDA for Impella CP heart pump with SmartAssist, utilizing an optical sensor, in 2018. 

Non-Small Cell Lung Cancer- Healthcare Journal Blog

The non-small cell lung cancer is a type of lung cancer arising in the epithelial tissue, and it is different than the small cell lung cancer. This non-small cell lung cancer is the most common lung cancer among the all types of lung cancers. Most often, treatment for NSCLC uses a combination of 2 chemo drugs. Studies have shown that adding a third chemo drug doesn’t add much benefit and is likely to cause more side effects.

The report defines the market of non-small cell lung cancer on the basis of the treatment types including Early/non-metastatic NSCLC, Advanced/metastatic NSCLC, EGFR mutations, ALK gene rearrangements, and other treatment options.

The air pollution is increasing rapidly across the all over the globe. According to the world health organization, the outdoor air pollution is the main cause of lung cancer. Rising smoking habit among the population and the increasing air population drives the market growth of non-small cell lung cancer therapeutics market. The American Cancer Society’s recorded an average about 2, 34,030 new cases of lung cancer and about 1, 54,050 deaths from lung cancer up to2018. Moreover, the ongoing R&D on non-small cell lung cancer therapies, growing focus on healthcare sectors, and introduction of new drugs are projected to create more opportunities in this market in upcoming years.

Geographically, North America dominates the market of non-small cell lung cancer therapeutics market. The government of North America supports the research activity that results in the up gradation of existing drugs and development of new advanced and effective drugs are increasing. The presence of major players and increased advancements in this sectors are expected to boost the market of non-small cell lung cancer therapeutics in this region between the periods of 2018 to 2024.

Dry Eye Syndrome | IGR

Dry eye can be used to describe dryness and inflammation of the cornea. Dry eye occurs when, either the eyes are not able to produce enough tears or when the tears evaporate too quickly. Dry eye syndrome is one of the most common eye disorders around the world and is particularly common in the geriatric demographic. Dry eye syndrome results from use of contact lens, allergies, pregnancy, vitamin A deficiency, LASIK surgery, and certain medications such as antihistamines, hormone replacement therapy, antidepressants and others. Symptoms associated with dry eye syndrome includes irritation, redness, discharge, and easily fatigued eyes.

 

The growth of the dry eye syndrome market is majorly due to combination of factors such as rising geriatric population around the world, growing prevalence of diabetes and increase awareness among the population concerning dry eye syndrome. However, Dry eye syndrome is likely to be ignored by many patients, since the inconvenience caused by it is not debilitating which affects the market growth. The rising awareness about the dry eye syndrome diagnosis & treatment can result in more number of patients proactively trying to cure the disease that may create lucrative opportunities for market growth.

 

The dry eye syndrome market is influenced mainly by North America region in 2017. The high prevalence of lifestyle disorders that increases the chances of contracting dry eye syndrome in this region is a major driver for the North America dry eye syndrome market. Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to growing healthcare infrastructure facilities and increasing population that is likely to increase the chance of people getting affected with dry eye syndrome.

 

Invisible in the Canal Hearing Aids

Hearing loss may also result from genetic causes, complications at birth, certain infectious diseases, chronic ear infections, the use of particular drugs, use of modern sound system and ultra-high definition technologies related music system, exposure to excessive noise, and ageing. Canal in the ear, is a tube running from the outer ear to the middle ear. New technology has developed small miniature hearing devices that are virtually unrecognizable or undetectable by normal observation.

One of the primary drivers for this market is the rising use of digital technologies for hearing aids. With the use of digital technology, the background noise can be eliminated. In some hearing aids, the background noise can be controlled by using volume controller and noise blocker. Furthermore, smartphones have been integrated with the hearing devices that helps hearing impairment patients in leading a normal lifestyle. The digital hearing aids are also equipped with more than one listening programs.

According to the World Health Organization (WHO), over 5% of the world’s population suffers from disabling hearing loss, totals over 360 million people across the globe. The majority of these people live in low and middle income countries, where the access to healthcare facilities and quality of health organizations is lower than that of the United States.

On the basis of region, the Canal Hearing Aids market is divided into North America, Europe, ASAP, and the Rest of the World (RoW). Europe is the dominant player among other regions in canal hearing market. Rapid rise in geriatric population, growing incidence prevalence of hearing loss, and high purchasing power of patients is projected to augment the market in the region. Asia Pacific is expected to grow at the highest CAGR during the forecast period, on account of improving healthcare infrastructure

Increasing number of aesthetics procedures, growing purchasing power and rising medical tourism are anticipated to boost the market for Medical Aesthetics

Mr. Athavale estimates that the medical aesthetic devices market will rise from a valuation of US$6.5 bn in 2015 to US$15.1 bn in 2024

North America has amassed the growth in Medical Aesthetics Market

The global Medical Aesthetics market has been dominated by the North America region over the historic period 2016-17 followed by Europe.

Presence of number of facilities which perform surgical and non-surgical procedures and increasing demand for minimally invasive procedures are the prime factor responsible for the growth of Medical Aesthetics market in this region.

Increasing number of aesthetics procedures, growing purchasing power and rising medical tourism are anticipated to boost the market for Medical Aesthetics.

Advancement in the technologies of medical aesthetic to boost the growth in Medical Aesthetics Market

Advancement in the technologies of medical aesthetic segment is one of the recent trends in the global Medical Aesthetics market.

This trend is further anticipated to drive the global Medical Aesthetics market over the forecast period. Furthermore, laser based medical aesthetic and advancement in the medical laser technologies of ultrasound are the key factors responsible for the growth of this trend as they are non-invasive and helps in fat reduction.

Growing demand for minimally invasive and non-invasive medical aesthetic procedures coupled with growing aging population are the key factor driving the grow of this market. Moreover, factors such as minimal surgical incision and no surgical incision in minimally invasive and non-invasive procedures are responsible for the growing demand of this procedure.

Leading Players in the Market

Ellman International, 3M Healthcare, Cynosure, Bioha Laboratories, Allergan, Merz Aestehtics, GROUPE SEBBIN, Nobel Biocare, Straumann and Establishment Labs.

 

Pharmaceutical Continuous Manufacturing Technology Reduces Manual Intervention Due to Control Units that Provide a High Level of Automation

Pharmaceutical continuous manufacturing technology reduces manual intervention due to control units that provide a high level of automation. Moreover, Initiatives by FDA to switch from current batch process to continuous manufacturing technology drives interest among the pharmaceutical companies. Furthermore, with the new level of productivity, Siemens is working to develop experimental plants with the help of continuous manufacturing, they are working in collaboration with the numbers of pharmaceutical companies as well as the original equipment manufacturers to boost the demand for Pharmaceutical Continuous Manufacturing.

Europe region is the largest consumer among the geographies followed by Asia-Pacific

The global pharmaceutical continuous manufacturing market has been dominated by the Europe region over the historic period 2015-16 followed by Asia-Pacific. The U.K. and Germany are the leading markets of Pharmaceutical Continuous Manufacturing in the g European region. Furthermore, the Asia-Pacific region is expected to grow at a highest CAGR over the period of 2018 to 2024. Moreover, the demand for advance technology from is high and presence of many contract-manufacturing organizations are anticipated to boost the market for Pharmaceutical Continuous Manufacturing.

Growing demand for Pharmaceutical Continuous Manufacturing among End-users

The demand for Pharmaceutical Continuous Manufacturing is on the rise in the world market, especially in End-user owing its benefits such as increased profitability, lower manufacturing and equipment cost, reduced inconsistency and so on.

This manufacturing technology provides the better way of manufacturing drug products that save time, improve quality, create more flexibility in production quantities, reduce required production and the material that is to be developed this may turn into the additional positive factor driving the demand growth worldwide.

Utilization of product capacity in the continuous manufacturing is driving the growth of pharmaceutical continuous manufacturing market

According to the United Nations Conference on Trade and Development (UNCTAD), productive capacity is the maximum possible output of an economy. Hence utilization of product capacity in the continuous manufacturing is driving the growth of the market significantly.

The growing demand for Pharmaceutical Continuous Manufacturing in the End-user segment is expected to drive the growth in this market over the forecast period.

Major Key Players in this Market

The companies covered in the report include Johnson & Johnson’s, GEA, Korsch AG, Siemens AG, Corning Life Sciences, Continuus Pharmaceutical, Scott Equipment Company, S K Biotek ltd, Chemtrix and Others.

For More Details@ https://bit.ly/2kV9CwV